Recent news and earnings transcripts highlight PROCEPT BioRobotics' Q1 2026 financial results, including a net loss but revenue exceeding estimates, driven by U.S. system sales and procedure expansion. Analyst coverage includes neutral and buy recommendations.

• PROCEPT reported a net loss for Q1 2026 but topped revenue estimates, with growth driven by U.S. system sales and increased procedure volumes [N2].
• The company held earnings calls and transcripts in April 2026 discussing Q1 results and business updates [N1,N3].
• Baird initiated coverage of PROCEPT with a neutral recommendation in March 2026 [N5].
• Truist Securities maintained a buy recommendation for PROCEPT in December 2025 [N5].

PROCEPT BioRobotics benefits from a growing installed base of robotic systems and expanding procedure volumes driven by increasing adoption of Aquablation therapy among urologists. The company's strong clinical evidence and inclusion in clinical guidelines support favorable reimbursement coverage, enabling broad patient access. Ongoing investments in clinical trials for prostate cancer and product innovation may open new market opportunities. The company's direct sales model and strategic accounts team aim to deepen penetration in existing hospitals and expand into integrated delivery networks. Strong liquidity supports continued commercialization and R&D efforts.

PROCEPT faces risks related to its reliance on single-source suppliers and a single manufacturing facility, which could disrupt supply and production. The company has a history of net losses and may require additional capital to fund operations and growth, with no assurance of favorable financing terms. Reimbursement rates and coverage policies could change, impacting procedure demand. Competition from alternative surgical and non-surgical treatments may limit market penetration. The company's commercial success depends on continued adoption by urologists and acceptance by payors, which may be slower or more limited than anticipated.

PROCEPT BioRobotics' moat is anchored in its proprietary Aquablation therapy technology, which combines robotic precision, real-time imaging, and personalized treatment planning to deliver consistent and reproducible outcomes independent of prostate size, shape, and surgeon experience. The company has built a robust clinical evidence base with multiple pivotal studies and peer-reviewed publications, supporting superior safety and efficacy compared to traditional surgical treatments. Its inclusion in clinical guidelines by major urological associations and broad Medicare and commercial payor coverage further strengthen its competitive position. The installed base of robotic systems and established relationships with key opinion leaders and urologists create barriers to entry for competitors.

• Supply Chain and Manufacturing Risks: PROCEPT relies on single-source suppliers for critical components and a single manufacturing facility, creating vulnerabilities to supply shortages, quality issues, and production delays that could adversely affect operations.
• Financial and Capital Risks: The company has a history of significant net losses and an accumulated deficit. It may need to raise additional capital to fund growth and operations, with potential dilution or unfavorable terms. Restrictive covenants in existing debt agreements may limit financial flexibility.
• Reimbursement and Regulatory Risks: Changes in Medicare, commercial payor coverage, or healthcare reform could reduce reimbursement rates or limit patient access, negatively impacting revenue. Regulatory approvals and compliance requirements pose ongoing challenges.
• Market Adoption and Competition Risks: Adoption of Aquablation therapy depends on urologist acceptance and patient demand. Competition from alternative treatments and technologies may limit market share and growth potential.
• Operational Risks: Scaling manufacturing and commercial operations involves risks including quality control, hiring and training, and maintaining customer satisfaction. Disruptions from natural disasters or other catastrophic events could impact facilities and supply chains.

• PROCEPT BioRobotics Corp is a surgical robotics company focused on developing and commercializing advanced image-guided robotic systems for minimally invasive urologic surgery, primarily treating benign prostatic hyperplasia (BPH) [S1].
• The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which deliver proprietary Aquablation therapy using a heat-free waterjet for targeted prostate tissue removal [S1].
• Aquablation therapy combines real-time multi-dimensional imaging, personalized treatment planning, automated robotics, and heat-free waterjet ablation to provide consistent and reproducible surgical outcomes independent of prostate size, shape, and surgeon experience [S1].
• As of December 31, 2025, PROCEPT had an installed base of 912 robotic systems globally, including 718 in the United States [S1].
• The total addressable market in the United States includes approximately 8 million men with BPH who are receiving drug therapy, have failed medication, or undergo surgical intervention, representing an estimated $30 billion market opportunity based on the average selling price of the disposable handpiece [S1].
• The company primarily sells its products to hospitals, distribution partners, ambulatory surgery centers, and leasing companies, with a direct sales organization focused on U.S. urologists at approximately 2,700 hospitals performing resective BPH surgeries [S1].
• PROCEPT offers sales-type leasing arrangements and its customers bill third-party payors, including commercial payors and government agencies, for procedure reimbursement [S1].
• Since 2021, all local Medicare Administrative Contractors cover Aquablation therapy for eligible Medicare patients in all 50 states, and the company estimates approximately 95% of men in the U.S. have access to the therapy through favorable commercial payor coverage [S1].
• The company is investing in clinical research, including multiple prostate cancer clinical trials (PRCT001, PRCT002, WATER IV PCa) to support future commercial, regulatory, and reimbursement efforts [S1].
• Manufacturing is conducted at a single facility in San Jose, California, with reliance on multiple single-source suppliers for components and sub-assemblies, which presents supply chain risks [S1].
• PROCEPT reported revenue of $308.1 million and net losses of $95.6 million for the year ended December 31, 2025, with an accumulated deficit of $641.6 million as of that date [S1].
• For the quarter ended March 31, 2026, the company reported a net loss of $31.6 million and basic and diluted EPS of -$0.56, with cash and cash equivalents of $245.6 million and a strong liquidity position including a current ratio of 6.73 and cash ratio of 3.86 [S2].
• The company has a loan and security agreement with Canadian Imperial Bank of Commerce with $52 million outstanding as of December 31, 2025, containing restrictive covenants and financial requirements [S1].
• PROCEPT faces risks including supply chain vulnerabilities due to single-source suppliers, manufacturing scale-up challenges, competitive pressures, reimbursement and regulatory uncertainties, and the need for additional capital to fund operations and growth [S1,S2].
• Recent news highlights include Q1 2026 earnings transcripts and reports of strong Q1 growth driven by U.S. system sales and procedure expansion, as well as reports of Q1 loss but revenue exceeding estimates [N1,N2,N3].
• Analyst coverage includes initiation by Baird with a neutral recommendation and Truist Securities maintaining a buy recommendation [N5].